CA2812570A1 - Formulations d'opioides a liberation controlee - Google Patents
Formulations d'opioides a liberation controlee Download PDFInfo
- Publication number
- CA2812570A1 CA2812570A1 CA2812570A CA2812570A CA2812570A1 CA 2812570 A1 CA2812570 A1 CA 2812570A1 CA 2812570 A CA2812570 A CA 2812570A CA 2812570 A CA2812570 A CA 2812570A CA 2812570 A1 CA2812570 A1 CA 2812570A1
- Authority
- CA
- Canada
- Prior art keywords
- oxycodone
- salt
- opioid
- pharmaceutical formulation
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38622710P | 2010-09-24 | 2010-09-24 | |
US61/386,227 | 2010-09-24 | ||
US13/024,319 | 2011-02-09 | ||
US13/024,319 US20110195989A1 (en) | 2010-02-09 | 2011-02-09 | Controlled Release Formulations of Opioids |
PCT/US2011/053132 WO2012040651A2 (fr) | 2010-09-24 | 2011-09-23 | Formulations d'opioïdes à libération contrôlée |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2812570A1 true CA2812570A1 (fr) | 2012-03-29 |
Family
ID=44741728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2812570A Abandoned CA2812570A1 (fr) | 2010-09-24 | 2011-09-23 | Formulations d'opioides a liberation controlee |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2618820A2 (fr) |
JP (1) | JP2013537915A (fr) |
CN (1) | CN103476403A (fr) |
AU (1) | AU2011305161A1 (fr) |
CA (1) | CA2812570A1 (fr) |
WO (1) | WO2012040651A2 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2957281A1 (fr) | 2001-09-21 | 2015-12-23 | Egalet Ltd. | Systeme de liberation a base de polymere |
WO2003024430A1 (fr) | 2001-09-21 | 2003-03-27 | Egalet A/S | Systeme a liberation de polymere de morphine |
DE602004031096D1 (de) | 2003-03-26 | 2011-03-03 | Egalet As | Morphin-system mit kontrollierter freisetzung |
CA2687192C (fr) | 2007-06-04 | 2015-11-24 | Egalet A/S | Compositions pharmaceutiques a liberation controlee pour un effet prolonge |
US9005660B2 (en) | 2009-02-06 | 2015-04-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
WO2010149169A2 (fr) | 2009-06-24 | 2010-12-29 | Egalet A/S | Formulations à libération contrôlée |
AU2013204592A1 (en) * | 2012-04-09 | 2013-10-24 | QRxPharma Ltd. | Controlled release formulations of opioids |
CA2877183A1 (fr) | 2012-07-06 | 2014-01-09 | Egalet Ltd. | Compositions pharmaceutiques de dissuasion d'abus a liberation controlee |
EP3169315B1 (fr) * | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Forme posologique remplie de liquide anti-abus à libération immédiate |
CN114515282B (zh) * | 2020-11-19 | 2023-09-08 | 山东大学 | Sorbic acid在制备抗冠状病毒感染药物中的应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US20060240105A1 (en) * | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
US6419960B1 (en) * | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
US20030092724A1 (en) * | 2001-09-18 | 2003-05-15 | Huaihung Kao | Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic |
EP1450824A4 (fr) * | 2001-11-02 | 2005-09-28 | Elan Corp Plc | Composition pharmaceutique |
US8906413B2 (en) * | 2003-05-12 | 2014-12-09 | Supernus Pharmaceuticals, Inc. | Drug formulations having reduced abuse potential |
JP2008526846A (ja) | 2005-01-05 | 2008-07-24 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 鎮痛性結合体 |
WO2006103418A1 (fr) * | 2005-03-28 | 2006-10-05 | Orexo Ab | Nouvelles compositions pharmaceutiques utiles dans le traitement de la douleur |
US20090082466A1 (en) | 2006-01-27 | 2009-03-26 | Najib Babul | Abuse Resistant and Extended Release Formulations and Method of Use Thereof |
WO2008057579A2 (fr) * | 2006-11-07 | 2008-05-15 | Nektar Therapeutics Al, Corporation | Formes dosifiées et co-administration d'un agoniste opioïde et d'un antagoniste opioïde |
AU2009203070A1 (en) * | 2008-05-20 | 2009-12-10 | Qrxpharma Limited | Dual opioid pain therapy |
US20110195989A1 (en) * | 2010-02-09 | 2011-08-11 | Rudnic Edward M | Controlled Release Formulations of Opioids |
-
2011
- 2011-09-23 EP EP11764653.9A patent/EP2618820A2/fr not_active Withdrawn
- 2011-09-23 CN CN2011800562785A patent/CN103476403A/zh active Pending
- 2011-09-23 WO PCT/US2011/053132 patent/WO2012040651A2/fr active Application Filing
- 2011-09-23 JP JP2013530379A patent/JP2013537915A/ja active Pending
- 2011-09-23 AU AU2011305161A patent/AU2011305161A1/en not_active Abandoned
- 2011-09-23 CA CA2812570A patent/CA2812570A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2011305161A1 (en) | 2013-05-09 |
EP2618820A2 (fr) | 2013-07-31 |
JP2013537915A (ja) | 2013-10-07 |
CN103476403A (zh) | 2013-12-25 |
WO2012040651A2 (fr) | 2012-03-29 |
WO2012040651A3 (fr) | 2012-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110195989A1 (en) | Controlled Release Formulations of Opioids | |
US20130022646A1 (en) | Controlled Release Formulations of Opioids | |
CA2812570A1 (fr) | Formulations d'opioides a liberation controlee | |
JP5844312B2 (ja) | 事故的誤用および不法転用を防止するための耐破砕性錠剤 | |
RU2599846C2 (ru) | Новые и эффективные лекарственые формы тапентадола | |
JP6550157B2 (ja) | Gaba類似体及びオピオイドを含む新規胃内滞留型剤形 | |
US20140193490A1 (en) | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats | |
IL235150A (en) | Pharmaceuticals | |
SG172818A1 (en) | Abuse resistant melt extruded formulation having reduced alcohol interaction | |
WO2009076764A1 (fr) | Formulation à libération contrôlée évitant les utilisations impropres | |
CA2301883A1 (fr) | Compositions contenant des unites multiples a liberation modifiee de substances medicamenteuses anti-inflammatoires non steroides (nsaid) | |
AU3687701A (en) | Controlled-release compositions containing opioid agonist and antagonist | |
NO323574B1 (no) | Multippelenhets doseringsmateriale for modifisert avgivelse | |
CA2627058A1 (fr) | Forme pharmaceutique orale microparticulaire anti-mesusage | |
MXPA04001210A (es) | Formulaciones de agonista opioide con antagonista liberable y aislado. | |
CN107213128A (zh) | 控释氢可酮制剂 | |
WO2010069050A1 (fr) | Composition à libération contrôlée prévenant un mésusage | |
WO2009088673A2 (fr) | Composition pharmaceutique | |
AU2013204592A1 (en) | Controlled release formulations of opioids | |
AU2018219999A1 (en) | Pharmaceutical composition | |
AU2014216026A1 (en) | Pharmaceutical composition | |
AU2012202717A1 (en) | Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |
Effective date: 20160923 |